Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients

Journal of Human Hypertension volume 16, pages 133–140 (2002)Cite this article

Abstract

The present study describes the effects of losartan and the angiotensin-converting enzyme inhibitor enalapril on blood pressure, echocardiographically calculated left ventricular mass, renal function evaluated by glomerular filtration rate and quality of life. The renin-angiotensin-aldosterone system is of importance for cardiovascular growth. There is substantial experimental documentation in animals that the angiotensin II antagonist, losartan, decreases the cardiac hypertrophy response caused by elevated arterial pressure as well as intravascular volume overload. However, data in humans is scarce. This is a 3-year, randomised, double-blind study with parallel group design in 50 patients with essential hypertension. The results show that both drugs reduced blood pressure equally effectively, and also left ventricular mass (P < 0.001). After 3 years of treatment glomerular filtration rate significantly increased with losartan (P < 0.005). Serum uric acid fell modestly although significantly, dose-dependent in losartan patients compared with an increase in enalapril patients. A fall in serum potassium from the pre-study period was observed in all patients. There was no difference between treatments in terms of patient satisfaction on quality of life. Both drugs have relatively similar hormonal and haemodynamic effect, with an excellent tolerability profile; they appear to induce comparable blood pressure falls in hypertensive patients in particular, therapy based on specific Ang II blockade may offer advantages in high risk hypertensives if left ventricular hypertrophy is present. Both enalapril and losartan, in improving the renal function attenuating the intrarenal effects of angiotensin II, might be able to reverse the pathophysiology of essential hypertensive kidney disease, and should be first-choice drugs in the treatment of essential hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Wexler RR et al. Rationale for the chemical development of angiotensin II receptor antagonists Am J Hypertens 1992 5 (Suppl): 209S–220S

    Article  Google Scholar 

  2. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF . Non-peptide angiotensin II receptor antagonists Trends Pharmacol Sci 1991 12: 55–62

    Article  CAS  PubMed  Google Scholar 

  3. Christen YJ et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II Circulation 1991 83: 1333–1342

    Article  CAS  PubMed  Google Scholar 

  4. Tsunoda K et al. Hypotensive effects of losartan, a non peptide angiotensin II receptor antagonist, in essential hypertension Am J Hypertens 1993 6: 28–32

    Article  CAS  PubMed  Google Scholar 

  5. Kaplan NM . Treatment of hypertension: drug therapy. In: Kaplan NH (ed.) Clinical Hypertension Williams & Wilkins: Baltimore, Md 1990 pp 182–267

    Google Scholar 

  6. Devereux RB . Evaluation of cardiac structure and function by echocardiography and other non-invasive techniques. In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, Diagnosis and Treatment Raven Press: New York 1990 1479–1492

    Google Scholar 

  7. Sahn DJ, De Maria A, Kisslo J, Weyman A . The Committee on M-mode standardisation of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 1978 58: 1072–1083

    Article  CAS  Google Scholar 

  8. Devereux RB et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings Am J Cardiol 1986 57: 450–458

    Article  CAS  PubMed  Google Scholar 

  9. Dahlof B . Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy Blood Press 1992 1 (Suppl 6): 1–75

    Google Scholar 

  10. Gates GF . Glomerular filtration rate: estimation from fractional renal accumulation of Tc-99m DTPA (stannous) Am J Roentgenol 1982 138: 565–570

    Article  CAS  Google Scholar 

  11. Gates GF . Spilt renal function testing using Tc-99m DTPA. A rapid technique for determining differential glomerular filtration Clin Nucl Med 1983 8: 400–407

    Article  CAS  PubMed  Google Scholar 

  12. Levine S, Croog SH . What constitutes quality of life? A conceptualisation of the dimensions of life quality in healthy populations and patients with cardiovascular disease. In: Wenger NK, Mattson ME, Furberg CD, Elison J (eds) Assessment of Quality of Life, in Clinical Trials of Cardiovascular Therapies Le Jacq Publishing: New York 1984 pp 46–58

    Google Scholar 

  13. Armitage P . Statistical Methods in Medical Research Blackwell Scientific Publications: New York 1971

    Google Scholar 

  14. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC . Effects of the non peptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal function in spontaneously hypertensive PH dogs Am J Hypertens 1991 4: 327S–333S

    Article  CAS  PubMed  Google Scholar 

  15. Weber MA . Clinical experience with the angiotensin II receptor antagonist losartan Am J Hypertens 1992 5: 247S–281S

    Article  CAS  PubMed  Google Scholar 

  16. Dahlof B, Pennert K, Hansson L . Reversal of left ventricular hypertrophy in hypertensivepatients a meta-analysis of 109 treatment studies Am J Hypertens 1992 5: 95–110

    Article  CAS  PubMed  Google Scholar 

  17. Lever AF . Slow developing pressor effect of angiotensin II and vascular structure J Hypertens 1993 11 (Suppl 3): S27–S28

    Google Scholar 

  18. Dzau VJ, Sasamura H, Hein L . Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications J Hypertens 1993 11 (Suppl 3): S13–S18

    Google Scholar 

  19. Husaln A . The chymase-angiotensin system in humans J Hypertens 1993 11: 1155–1159

    Google Scholar 

  20. Schunkert H et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy N Engl J Med USA 1994 330: 1634–1638

    Article  CAS  Google Scholar 

  21. Brunner HR . ACE inhibitors in renal disease Kidney Int 1992 42: 463–479

    Article  CAS  PubMed  Google Scholar 

  22. Steinhausen M et al. Different responses of cortical and juxtamedullary arterioles to norepinephrine and angiotensin II Kidney Int 1990 38 (Suppl 30): S55–S59

    Google Scholar 

  23. Nakashima M, Uematsu T, Kosuge K, Kanamura M . Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects Eur J Clin Pharmacol 1992 42: 333–335

    Article  CAS  PubMed  Google Scholar 

  24. Burnier M et al. Salt dependent renal effects of an angiotensin II antagonist in healthy subjects Hypertension 1993 22: 339–347

    Article  CAS  PubMed  Google Scholar 

  25. Waeber B, Nussberger J, Brunner HR . Angiotensin-converting enzyme inhibitors in hypertension. In: Laragh JH, Brenner BM (eds) Hypertension: Patho-physiology, Diagnosis and Management Raven Press: New York 1990 pp 2209–2232

    Google Scholar 

  26. Lacourciére Y et al. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study J Hypertens 1994 12 (Suppl 2): S49–S53

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Internal Medicine and Geriatry, Faculty of Medicine, University ‘Federico II’, Naples, Italy

    M L De Rosa, P Cardace, M Rossi, A Baiano & A de Cristofaro

Authors
  1. M L De Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Cardace
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Baiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A de Cristofaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M L De Rosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Rosa, M., Cardace, P., Rossi, M. et al. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 16, 133–140 (2002). https://doi.org/10.1038/sj.jhh.1001305

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001305

Keywords

This article is cited by

Search

Advanced search

Quick links